title: Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
authors.affiliation: Seattle.
authors.forename: Michael
authors.initials: M
authors.lastname: McCarthy
mesh_terms: D026683:Advisory Committees; D001562:Benzimidazoles / Q000191:economics / Q000627:therapeutic use; D016265:Conflict of Interest / Q000191:economics*; D016527:Drug Costs / Q000941:ethics*; D004345:Drug Industry / Q000191:economics* / Q000941:ethics*; D004994:Ethics, Pharmacy; D035082:Federal Government; D005252:Fees, Pharmaceutical / Q000941:ethics* / Q000706:statistics & numerical data*; D005449:Fluorenes / Q000191:economics / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D058028:Research Report; D000069474:Sofosbuvir / Q000191:economics* / Q000627:therapeutic use*; D014481:United States; D014542:Uridine Monophosphate / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
chemical_list: D001562:Benzimidazoles; D005449:Fluorenes; C000595958:ledipasvir, sofosbuvir drug combination; D014542:Uridine Monophosphate; D000069474:Sofosbuvir